Xiaoaiping Injection Combined with Cisplatin and Gemcitabine for Non-Small Cell Lung Cancer: A Clinical ObservationΔ

FANG Huan,WANG Jing,PAN Chun-feng,GUO Shui-gen,CHU De-jie,ZHANG Jun

DOI: https://doi.org/10.14009/j.issn.1672-2124.2013.02.020

2013-01-01

Abstract:OBJECTIVE:To evaluate the efficacy and safety of Xiaoaiping injection combined with cisplatin plus gemcitabine(regimen of GP) for patients with non-small cell lung cancer(NSCLC) and the quality of life of the NSCLC patients treated with the this combined therapy.METHODS: A total of 86 patients with advanced NSCLC meeting the inclusion criteria were randomly assigned to receive either GP alone or GP plus Xiaoaiping injection.The objective evaluation criteria for solid tumors as recommended by WHO,the grading criteria for acute/subacute toxicity of chemotherapeutic drugs as recommended by WHO,and the observer score of lung cancer symptom scale(LCSS) were used for evaluation of the efficacy and safety of the chemotherapy and the quality of life of the patients.Kaplan-Meier and Life-time Table were used for survival analysis.RESULTS: The differences between two groups in median survival time,1-year and 1.5-year survival rates were not significant.The incidence rates of leucopenia of grade Ⅲ-Ⅳ reduction of hemoglobin,reduction of blood platelet count,and nausea & vomiting of grade Ⅲ-Ⅳ were 48.8%,39.5%,37.2% and 23.3%,respectively in GP group as compared with 16.3%,20.9%,18.6% and 7.0% respectively in GP plus Xiaoaiping injection group(P<0.05).LCSS score indicated that in patients treated with GP therapy alone,there was little improvement in symptoms of dyspnea and hemoptysis;however in those treated with GP plus Xiaoaiping injection,all the symptoms had improvement after chemotherapy(P<0.05).CONCLUSION: Xiaoaiping injection as the adjuvant therapy for GP regimen was proved to be safe and effective for improving body function while attenuating the toxic side effect of GP chemotherapy in NSCLC patients.As compared with the GP therapeutic regimen alone,the GP plus Xiaoaiping injection regimen was more acceptable in patients with advanced NSCLC hence it is worthy of clinical popularization and application.